Abstract
Methoxetamine is a dissociative anaesthetic showing pharmacodynamic similarities with its analogue ketamine, a medication with demonstrated rapid-acting antidepressant effects. Like ketamine and other arylcyclohexylamine compounds, methoxetamine is thought to be both a noncompetitive NMDA receptor antagonist and a dopamine reuptake inhibitor. Furthermore, it acts as an agonist at dopamine D2, serotonin 5HT2, muscarinic cholinergic, sigma-1, opioid mu and k receptors. The hypothesis is that methoxetamine can produce rapid antidepressant effects in patients with resistant and non-resistant unipolar and bipolar depression.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Anesthetics, Dissociative / pharmacology
-
Animals
-
Antidepressive Agents / pharmacology*
-
Bipolar Disorder / drug therapy
-
Cyclohexanones / pharmacology*
-
Cyclohexylamines / pharmacology*
-
Depressive Disorder / drug therapy
-
Humans
-
Illicit Drugs / pharmacology
-
Ketamine / pharmacology
-
Models, Biological
-
Receptors, Muscarinic / drug effects
-
Receptors, N-Methyl-D-Aspartate / drug effects
-
Receptors, Opioid / drug effects
-
Receptors, sigma / drug effects
Substances
-
Anesthetics, Dissociative
-
Antidepressive Agents
-
Cyclohexanones
-
Cyclohexylamines
-
Illicit Drugs
-
Receptors, Muscarinic
-
Receptors, N-Methyl-D-Aspartate
-
Receptors, Opioid
-
Receptors, sigma
-
Ketamine
-
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone